Welcome to CMTTdb
The integrated database for cancer molecular-targeted therapies (CMTTdb) v1.0 is a database containing information about the molecules used as targeted agents for the treatment of cancer, as well as their combinatorial approaches in clinical trials and studies. The database is intended to help guide oncologists in establishing optimal cancer therapies. It is an integrated resource available for use from the bench up to clinical settings. The intention is for the database to become a bridge between these two points that provides access to the explosion of information about molecularly targeted agents in clinical trials for solid tumors in the era of precision medicine.
Although several established databases have facilitated target and drug discovery and validation, there is still room for making these resources available in clinical use. The rapid introduction of mutation-targeted agents into the therapies for suitable subgroups of patients would be beneficial; however, all of the established databases lack information on clinical results. At the same time, different combination modalities of targeted agents with other cancer therapies and biomarker testing are advancing at a staggering rate. Therefore, a public database that gives access to that clinical trial data and booming new targeted agents is greatly needed. The integrated database for cancer molecular-targeted therapies (CMTTdb) v1.0 is designed to provide information from published randomized clinical trials about mutation-targeted agents, the corresponding targets, biomarkers, targeted cancer subtypes, selected patient information, and the treatment modalities (monotherapy or combination with other therapies) reported to date. There is also a focus on clinical efficacy parameters (MTD, DLT, ORR, DCR, PFS, OS), adverse events and clinical implications. A major advantage of our database is that it illustrates how to use the drugs and the combinatorial therapeutic concepts. Furthermore, hyperlinks to other databases enhance access to the wealth of information about the extensive target and pathway data, clinical trial information, up-to-date therapeutic information for cancer, and the reference PMID. Until recently, our database contained 1088 entries, 159 targets, 171 agents covering 35 types of solid tumors, and 201 subtypes, including monotherapies (accounts for 43%) and combination therapies (accounts for 57%, with 18 kinds of combination modes).
Users can gain an overview of the targeted cancer therapies landscape by obtaining information about:
- The design and results of clinical trials and the references.
- The information behind the targeted agents, drug status, their corresponding targets, targets information, pathway information, and updated cancer therapeutic information.